Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Medical technology company, Aerocrine's product, NIOX MINO has earned market approvals in the South Korean and Taiwan.
Subscribe to our email newsletter
NIOX MINO enables management of airway inflammation and thus is believed to play a critical role in effective diagnosis, treatment and follow-up of patients with inflammatory airway diseases such as asthma.
According to the company, an approval is a key advancement towards receiving reimbursement for inflammation monitoring with the help of FeNO in asthma management.
The decision of the market approval in Korea was taken by Korea Food & Drug Administration (KFDA) while that in Taiwan was taken by Taiwan Food & Drug Administration (TFDA).